You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,172,815

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,172,815

Title:	Targeted treatment of anerobic cancer
Abstract:	The present invention relates to a pharmaceutical cocktail and methods of cancer treatment. In particular, one such cocktail comprises a combination of effective amounts of a lactate transporter inhibitor, a carbonic anhydrase inhibitor, a sodium potassium chloride cofactor (NKCC) transporter inhibitor, a member of the hydroxycinnamate class of drugs or a derivative thereof, and/or an angiogenesis inhibitor, including a vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab in combination with blood vessel occlusion. As most cancers in an untreated state uses both aerobic and anaerobic/glycolytic pathways treatments contemplated herein can affect both metabolic pathways.
Inventor(s):	Haaga; John R (Chagrin Falls, OH), Haaga; Rebecca (Chagrin Falls, OH)
Assignee:	UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (Cleveland, OH)
Application Number:	15/035,397
Patent Claims:	1. A method for treating a patient with cancer, said method comprising: a) administering an effective amount of a composition comprising a lactate transporter inhibitor to a patient comprising a cancerous lesion, wherein the cancerous lesion comprises a plurality of blood vessels, wherein said lactate transporter inhibitor is selected from the group consisting of ferrulic acid, caffeic acid, chlorogenic acid, resveratrol ferulate, and phloretin ferulate, and b) occluding at least one of said plurality of blood vessel. 2. The method according to claim 1 wherein said composition is delivered via liposomes. 3. The method according to claim 1 wherein the method further comprises administering to said patient an effective amount of an angiogenesis inhibitor. 4. The method according to claim 3 wherein said angiogenesis inhibitor is a humanized monoclonal antibody. 5. The method of claim 4, wherein said antibody is bevacizumab. 6. The method according to claim 3 wherein said treating comprises repeated administration of a composition comprising at least one of the following: lactate transporter inhibitor and angiogenesis inhibitor. 7. The method according to claim 1 wherein said cancer is hypoxic cancer. 8. The method according to claim 1 wherein said occluding further comprises an embolism. 9. The method according to claim 8 wherein said embolism is produced by the introduction of an embolic composition. 10. The method according to claim 9 wherein said embolic composition comprises a plurality of polymers embedded with lactate transporter inhibitors. 11. The method according to claim 9 wherein said embolic composition comprises a plurality of glass beads coated with at least one lactate transporter inhibitor. 12. The method according to claim 1 wherein said occluding of blood vessels providing blood to said cancer comprises thermal ablation. 13. The method according to claim 12 wherein said treating of said cancer with thermal ablation is preceded with lactate transporter inhibitor treatment. 14. A method for shrinking a cancerous lesion in a patient with cancer, said method comprising: a) administering an effective amount of a composition comprising a lactate transporter inhibitor to a patient comprising a cancerous lesion, wherein the cancerous lesion comprises a plurality of blood vessels, wherein said lactate transporter inhibitor is selected from the group consisting of ferrulic acid, caffeic acid, chlorogenic acid, resveratrol ferulate, and phloretin ferulate, and b) occluding at least one of said plurality of blood vessel. 15. A method of treating cancer comprising administering to a patient a composition comprising an effective amount of a lactate transporter inhibitor, a NKCC inhibitor, and an angiogenesis inhibitor, wherein said lactate transporter inhibitor is selected from the group consisting of ferrulic acid, caffeic acid, chlorogenic acid, resveratrol ferulate, and phloretin ferulate and wherein said NKCC inhibitor comprises bumetanide. 16. The method according to claim 15 wherein said composition is delivered via liposomes. 17. The method according to claim 15 wherein said angiogenesis inhibitor is a humanized monoclonal antibody. 18. The method of claim 17, wherein said antibody is bevacizumab. 19. The method according to claim 15 wherein said composition comprising at least one lactate transporter inhibitor, NKCC inhibitor, and an angiogenesis inhibitor is administered as a pharmaceutical cocktail. 20. The method according to claim 15 wherein said treating comprises repeated administration of at least one of the lactate transporter inhibitor, NKCC inhibitor, and an angiogenesis inhibitor. 21. The method according to claim 15 wherein said cancer is hypoxic cancer.

Details for Patent 10,172,815

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2033-11-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.